Xalkori (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15
4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Xalkori (crizotinib) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37
7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 44
7.3 Methodology 47
7.4 Forecasting Methodology 47
7.4.1 Number of NSCLC Patients Currently Seeking Treatment 47
7.4.2 Percent Drug-treated Patients 48
7.4.3 General Pricing Assumptions 48
7.4.4 Individual Drug Assumptions 51
7.4.5 Generic Erosion 52
7.5 Physicians and Specialists Included in This Study 52
7.6 Survey of Prescribing Physicians 54
7.7 About the Authors 55
7.7.1 Author 55
7.7.2 Epidemiologist 55
7.7.3 Global Head of Healthcare 56
7.8 About GlobalData 57
7.9 Disclaimer 57